Moleculin Secures $5.9M Funding: Major Push for Late-Stage Cancer Drug Development - Stock Titan
15 hours ago • Google News
Moleculin Biotech Inc (MBRX)
US$ 1.77-7.81%
Price Chart
Key Statistics
Market Cap
$ 3.77M
P/E Ratio
0.00
Revenue (TTM)
$ 0
Volume
5.04M
52W High
$ 4.71
52W Low
$ 0.25
Dividend Yield
0.00%
Beta
1.56
Technicals
50-Day MA
0.878
200-Day MA
1.672
52 Week High
4.707
52 Week Low
0.25
About MBRX
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses.
Employees
17
Headquarters
Houston, TX
CEO
Mr. Walter V. Klemp
Latest News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg